Literature DB >> 21215727

Methylphenidate normalizes emotional processing in adult patients with attention-deficit/hyperactivity disorder: preliminary findings.

Annette Conzelmann1, Eva Woidich, Ronald F Mucha, Peter Weyers, Christian P Jacob, Klaus-Peter Lesch, Paul Pauli.   

Abstract

Emotional-motivational dysfunctions may significantly contribute to symptoms of attention-deficit/hyperactivity disorder (ADHD). Hyperactive-impulsive symptoms and sensation seeking could be the result of a search for reinforcers, and cognitive dysfunctions might be due to a low motivational drive. Emotional-motivational dysfunctions could also explain social dysfunctions in ADHD patients because they may lead to misinterpretations of emotional and social clues. Since methylphenidate (MPH) is the first choice as a pharmacological treatment in ADHD, we examined its influence on dysfunctional emotional processes. 13 adult ADHD patients were examined twice, without and after intake of MPH according to their personal medication regimen. The affect-modulated startle paradigm was used to assess physiological (affect-modulated startle response) and subjective (valence and arousal ratings) responses to pleasant, neutral and unpleasant visual stimuli. Healthy controls displayed affective startle modulation as expected, with startle attenuation and potentiation while watching pleasant and unpleasant pictures, respectively. In contrast, unmedicated ADHD patients displayed deficient responses to pleasant stimuli; no startle attenuation during the exposure to pleasant pictures was observed. However, MPH reinstated a normal affective startle modulation, as indicated by attenuation and potentiation associated with pleasant and unpleasant pictures, respectively. Valence and arousal ratings of patients were not affected by MPH. The data suggest that MPH as first choice treatment in ADHD has a positive impact on emotional processes in adult ADHD patients and points to the clinical relevance of emotional-dysfunctions in ADHD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215727     DOI: 10.1016/j.brainres.2010.12.085

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Modulation of social influence by methylphenidate.

Authors:  Daniel K Campbell-Meiklejohn; Arndis Simonsen; Mads Jensen; Victoria Wohlert; Trine Gjerløff; Jørgen Scheel-Kruger; Arne Møller; Chris D Frith; Andreas Roepstorff
Journal:  Neuropsychopharmacology       Date:  2012-02-08       Impact factor: 7.853

2.  Oxytocin facilitates protective responses to aversive social stimuli in males.

Authors:  Nadine Striepens; Dirk Scheele; Keith M Kendrick; Benjamin Becker; Lea Schäfer; Knut Schwalba; Jürgen Reul; Wolfgang Maier; René Hurlemann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-16       Impact factor: 11.205

Review 3.  Emotion dysregulation in attention deficit hyperactivity disorder.

Authors:  Philip Shaw; Argyris Stringaris; Joel Nigg; Ellen Leibenluft
Journal:  Am J Psychiatry       Date:  2014-03       Impact factor: 18.112

4.  Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder.

Authors:  Annette Conzelmann; Eva Woidich; Ronald F Mucha; Peter Weyers; Mathias Müller; Klaus-Peter Lesch; Christian P Jacob; Paul Pauli
Journal:  J Neural Transm (Vienna)       Date:  2016-02-06       Impact factor: 3.575

5.  Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

Authors:  Pavel Golubchik; Jonathan Sever; Abraham Weizman
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

6.  Hot executive control and response to a stimulant in a double-blind randomized trial in children with ADHD.

Authors:  Jessica Yarmolovsky; Tamar Szwarc; Miguel Schwartz; Emanuel Tirosh; Ronny Geva
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-03-10       Impact factor: 5.270

7.  Adult attention-deficit hyperactivity disorder, risky behaviors, and motorcycle injuries: a case-control study.

Authors:  Homayoun Sadeghi-Bazargani; Leili Abedi; Minoo Mahini; Shahrokh Amiri; Davoud Khorasani-Zavareh
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-07       Impact factor: 2.570

8.  Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model.

Authors:  S Aga-Mizrachi; A Cymerblit-Sabba; O Gurman; A Balan; G Shwam; R Deshe; L Miller; N Gorodetsky; N Heinrich; O Tzezana; S Zubedat; D Grinstein; A Avital
Journal:  Transl Psychiatry       Date:  2014-09-23       Impact factor: 6.222

Review 9.  Driving and attention deficit hyperactivity disorder.

Authors:  Anselm B M Fuermaier; Lara Tucha; Ben Lewis Evans; Janneke Koerts; Dick de Waard; Karel Brookhuis; Steffen Aschenbrenner; Johannes Thome; Klaus W Lange; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2015-09-29       Impact factor: 3.575

10.  Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

Authors:  Mireia Pagerols; Vanesa Richarte; Cristina Sánchez-Mora; Paula Rovira; María Soler Artigas; Iris Garcia-Martínez; Eva Calvo-Sánchez; Montse Corrales; Bruna Santos da Silva; Nina Roth Mota; Marcelo Moraes Victor; Luis Augusto Rohde; Eugenio Horacio Grevet; Claiton Henrique Dotto Bau; Bru Cormand; Miguel Casas; Josep Antoni Ramos-Quiroga; Marta Ribasés
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.